Galmed Pharmaceuticals Stock Investor Sentiment

GLMD Stock  USD 2.76  0.06  2.13%   
About 61% of Galmed Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Galmed Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Galmed Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Galmed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at investorplace.com         
Wall Street Favorites 3 Penny Stocks With Strong Buy Ratings for April 2024
sbwire news
over six months ago at news.google.com         
Galmed Pharmaceuticals Research Coverage Started at StockNews.com - Defense World
Google News at Macroaxis
over six months ago at investorplace.com         
GLMD Stock Earnings Galmed Pharmaceuticals Misses EPS for Q4 2023
sbwire news
over six months ago at finance.yahoo.com         
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, ...
Yahoo News
over six months ago at news.google.com         
Galmed Pharmaceuticals Earns Sell Rating from Analysts at StockNews.com - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Galmed Pharmaceuticals Receives New Coverage from Analysts at StockNews.com - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief...
Yahoo News
over six months ago at news.google.com         
Galmed Pharmaceuticals Granted Nasdaq Extension - TipRanks.com - TipRanks
Google News at Macroaxis
over six months ago at news.google.com         
Galmed Pharmaceuticals Stock Price Crosses Below 200 Day Moving Average of 0.45 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Galmed Pharmaceutica Stock Quote Stock Price for GLMD FinancialContent Business Page - Financial Con...
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Galmed Pharmaceuticals Coverage Initiated by Analysts at StockNews.com
news
over six months ago at news.google.com         
Galmed Pharmaceuticals Stock Price Passes Below 200-Day Moving Average of 0.47 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Galmed Pharmaceuticals Earns Sell Rating from Analysts at StockNews.com - Defense World
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Galmed Pharmaceuticals Earns Sell Rating from Analysts at StockNews.com
news
over six months ago at thelincolnianonline.com         
Galmed Pharmaceuticals Now Covered by StockNews.com
news
Far too much social signal, news, headlines, and media speculation about Galmed Pharmaceuticals that are available to investors today. That information is available publicly through Galmed media outlets and privately through word of mouth or via Galmed internal channels. However, regardless of the origin, that massive amount of Galmed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Galmed Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Galmed Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Galmed Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Galmed Pharmaceuticals alpha.

Galmed Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Galmed Stock analysis

When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.